Evaluating the risk factors for liver injury in patients with chronic lymphocytic leukemia in the dynamics of chemotherapy

G.S. Maslova, I.M. Skrypnyk


Background. B-cell chronic lymphocytic leukemia (B-CLL) treatment is accompanied by a risk of liver injury due to factors that depend on the characteristics of the patient, tumor, and chemotherapy (CT). The purpose was to assess the risk of development and nature of liver injury in patients with B-CLL in the dynamics of CT. Materials and methods. Seventy-six patients with В-CLL were examined, including 44 (57.9 %) men and 32 (42.1 %) women. The average age was (66.81 ± 12.50) years. The B-CLL stage was determined according to the Rai (1975, 1987) and Binet (1981, 2006) classifications. CT was administered in FC (fludarabine, cyclophosphamide) regimen. The patients were examined twice: before CT and after two FC courses. Hyperplastic syndrome and hyperleukocytosis were taken into account. Biochemical blood tests were evaluated. Common Terminology Criteria for Adverse Events, version 4.02, were used. Results. Advanced B-CLL stages (stage IV (C) according to Rai, Binet) are associated with an increased risk of no response on CT (risk ratio (RR) = 0.53; 95% confidence interval (CI) = 0.31–0.90; p < 0.05). The presence of hyperplastic syndrome is accompanied by a significant risk of no response on CT (RR = 0.23; 95% CI = 0.07–0.80; p < 0.05). Liver injury is more often detected in patients with B-CLL stages III (RR = 1.96; 95% CI = 1.33–2.88; p < 0.05) and IV (RR = 2.13; 95% CI = 1.47–3.08; p < 0.05) versus stage II by Rai. In patients with B-CLL, the risk of hepatotoxic reactions development is associated with low efficacy of CT, namely the achievement of partial response (RR = 3.18; 95% CI = 1.93–5.22; p < 0.05) and no response on CT (RR = 3.71; 95% СІ = 2.37–5.81; р < 0.05). Conclusions. The risk of liver injury increases in patients with B-CLL stage IV (C) and is associated with low CT efficacy.


В-cell chronic lymphocytic leukemia; risk factors; hepatotoxic reactions; chemotherapy


Gluzman DF, Sklyarenko LM, Ivanivskaya TS, et al. Chronic lymphocytic leukemia and ionizing radiation. Oncology. 2016;18(2):84-92. (in Russian).

Domnikova NP, Nepomnyashchikh GI, Teterina NV. Clinical features of liver injury in patients with haemoblastosis. Bulletin of Siberian Branch of Russian Academy of Medical Science. 2008;28(6):41-46. (in Russian).

Kriachok IA. Chronic lymphcytic leukemia: new in treatment. Approaches to the first-line treatment and their evolution. Clinical oncology. 2013;(11):121-129. (in Russian).

Nepomnyashchikh GI, Postnikova OA, Domnikova NP, Bakarev MA. Morphological analysis of liver pathology in patients with acute leukemia and lymphoproliferative diseases. Siberian Journal of Oncology. 2012;(49):26-30. (in Russian).

Skrypnyk IM, Maslova GS. The evaluation of frequency and character of hepatotoxic reactions in patients with acute myeloid leukemia in the dynamics of remission induction. Modern Gastroenterology. 2018;(100):16-22. (in Ukrainian).

Philchenkov AA, Sklyarenko LM. Chronic lymphocytic leukemia: problems of diagnosis and therapy. Oncology. 2017;19(4):236-246. (in Russian).

Dores GM, Anderson WF, Curtis RE, et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol. 2007 Dec;139(5):809-19. doi: 10.1111/j.1365-2141.2007.06856.x.

Keating MJ. The use of fludarabine in chronic lymphocytic leukemia and malignant lymphomas. In: Hiddemann W, Plunkett W, Büchner T, et al., editors. Acute Leukemias V. Haematology and Blood Transfusion. Vol 37. Acute Leukemias V. Berlin, Heidelberg: Springer; 1996. 572-577 pp.

Nabhan C, Aschebrook-Kilfoy B, Chiu BC, et al. The impact of race, ethnicity, age and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive Surveillance, Epidemiology, and End Results analysis in the modern era. Leuk Lymphoma. 2014 Dec;55(12):2778-84. doi: 10.3109/10428194.2014.898758.

Noone AM, Cronin KA, Altekruse SF, et al. Cancer incidence and survival trends by subtype using data from the Surveillance Epidemiology and End Results Program, 1992-2013. Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):632-641. doi: 10.1158/1055-9965.EPI-16-0520.

Oscier D, Wade R, Davis Z, et al. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica. 2010 Oct;95(10):1705-12. doi: 10.3324/haematol.2010.025338.

Parikh SA. Chronic lymphocytic leukemia treatment algorithm 2018. Blood Cancer J. 2018 Oct 3;8(10):93. doi: 10.1038/s41408-018-0131-2.

Parikh SA, Chaffee KG, Larson MC, et al. Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis. Haematologica. 2018 Jun;103(6):e237-e240. doi: 10.3324/haematol.2017.183194.

Zenz T, Gribben JG, Hallek M, Döhner H, Keating MJ, Stilgenbauer S. Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood. 2012 May 3;119(18):4101-7. doi: 10.1182/blood-2011-11-312421.

Copyright (c) 2019 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2019


   Seo анализ сайта